none
Conditions
Interventions
three:irbesartan and erythromycin
Sponsors
Institute of Clinical Pharmacology, Central South University, Changsha, Hunan
Eligibility
Sex/Gender
Male
Age
18 Years to 45 Years
Inclusion criteria
Inclusion criteria: 1. Healthy participants, aged from 18 to 45 years, BMI 19 to 25 kg/m2; 2. No addiction to alcohol or drugs, non-smokers; 3. Healthy participants confirmed by physical examination, disease history, vital signs, ECG and laboratory tests; with no diseases of heart, liver, kidney, gastrointestinal system, neurological system; with no psychiatric or metabolic disorders; 4. With normal BP, HR, ECG, respiratory rate, liver and kidney function, and blood count; 5. Sign the written informed consent before the study; 6. With sufficient ability to communicate and to fulfill the study.
Exclusion criteria
Exclusion criteria: 1. Allergic to active pharmaceutical ingredients; 2. With gastrointestinal tract diseases; 3. With history of drug abuse within five years; 4. Use of drugs that might cause injury to organs within three months; 5. Use of other drugs within 14 days before the study; 6. Participates in other trials within 3 months; 7. Suffer from severe blood loss within 30 days before the study; 8. With diseases of primary organs; 9. Smokers or alcohol abusers; 10. Addictive to sedative and other drugs; 11. Patients that researchers regard not eligible for inclusion.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| plasma concentration of repaglinide;plasma concentration of irbesartan;plasma concentration of erythromycin;blood sugar; | — |
Countries
China
Contacts
Public ContactZhao-Qian Liu
Outcome results
None listed